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Abstract
Background: Type 2 diabetes mellitus (T2DM) is a chronic disease in which health outcomes are related to decision making
by patients and health care professionals.
Objective: This study aims to assess the effectiveness of internet-based multicomponent interventions to support decision
making of all actors involved in the care of patients with T2DM in primary care.
Methods: The INDICA study is an open, community-based, multicenter trial with random allocation to usual care or the
intervention for patients, the intervention for health care professionals in primary care, or the combined intervention for both. In
the intervention for patients, participants received an educational group program and were monitored and supported by logs, a
web-based platform, and automated SMS. Those in the intervention for professionals also received an educational program, a
decision support tool embedded in the electronic clinical record, and periodic feedback about patients’ results. A total of 2334
people with T2DM, regardless of glycated hemoglobin (HbA1c) levels and without diabetes-related complications, were included.
The primary end point was change in HbA1c level. The main analysis was performed using multilevel mixed models.
Results: For the overall sample, the intervention for patients attained a significant mean reduction in HbA1c levels of  0.27 (95%
CI  0.45 to  0.10) at month 3 and  0.26 (95% CI  0.44 to  0.08) at month 6 compared with usual care, which remained marginally
significant at month 12. A clinically relevant reduction in HbA1c level was observed in 35.6% (191/537) of patients in the
intervention for patients and 26.0% (152/586) of those in usual care at month 12 (P=.006). In the combined intervention, HbA1c
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reduction was significant until month 18 (181/557, 32.6% vs 140/586, 23.9%; P=.009). Considering the subgroup of patients
uncontrolled at baseline, all interventions produced significant reductions in HbA1c levels across the entire study period:  0.49
(95% CI  0.70 to  0.27) for the intervention for patients,  0.35 (95% CI  0.59 to  0.14) for the intervention for professionals, and
 0.35 (95% CI  0.57 to  0.13) for the combined intervention. Differences in HbA1c for the area under the curve considering the
entire period were significant for the intervention for patients and the combined intervention compared with usual care (P=.03
for both). Compared with usual care, the intervention for professionals and the combined intervention had significant longer-term
reductions in systolic and diastolic blood pressure.
Conclusions: In uncontrolled patients, the intervention for patients at baseline provided clinically relevant and significant
longer-term reductions of HbA1c levels. The intervention for professionals and combined intervention also improved the
cardiovascular risk profile of patients.
Trial Registration: ClinicalTrials.gov NCT01657227; https://clinicaltrials.gov/ct2/show/NCT01657227
(JMIR Mhealth Uhealth 2020;8(11):e18922) doi: 10.2196/18922
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Introduction
Background
Type 2 diabetes mellitus (T2DM) is a chronic condition in which
long-term health outcomes are related to patients’ adherence to
lifestyle modifications and pharmacologic treatments. Other
stakeholders, such as relatives and primary health care
professionals, are also involved in guiding patients’ decisions.
Although the prevalence of T2DM in the Canary Islands is
slightly higher than the average in Spain [1], the incidence of
chronic diabetes-related complications [2,3] and mortality [4]
is much greater. This occurs despite a continuous increase in
diabetes-related public expenditure [5].
Regardless of the widespread availability of evidence-based
clinical practice guidelines (CPGs) to care for T2DM, patients’
access to effective educational interventions [6] and adherence
to self-management activities remains limited internationally
[7].
To address these unmet needs, many publications have reported
on the effectiveness of using information and communications
technology (ICT) applications to support decision making by
patients and professionals [8-12], reporting favorable short-term
effects on blood glucose control [11,12]. The effectiveness of
other biological, cognitive, behavioral, or emotional outcome
measures remains controversial [11]. Few large randomized
controlled trials (RCTs) have assessed the long-term
effectiveness of multicomponent ICT-based interventions, not
only for patients but also for all stakeholders involved in
diabetes management.
Objectives
The INDICA study is a cluster RCT conducted in the Canary
Islands that assesses the effectiveness and cost-effectiveness of
multicomponent interventions to support decision making for
the main actors involved in the management of T2DM (patients,
relatives, and primary health care professionals) in a large
number of primary health care practices (PHCPs) [13]. We
hypothesized that combining conventional educational activities
with different ICT-based decision support tools would efficiently
improve health outcomes in patients with T2DM. The main
purpose of this study is to evaluate the long-term clinical
effectiveness (24 months) of these multicomponent interventions
compared with usual care on glycated hemoglobin (HbA1c).
Methods
Study Design
The INDICA study is an open, community-based pragmatic,
multicenter, clinical controlled trial with random allocation by
clusters to usual care or to one of the following 3 interventions
of knowledge transfer and behavior modification:
• Group 1 included interventions for patients and a family
member (intervention for patients)
• Group 2 included interventions for health care professionals
(physicians and nurses) at primary care (intervention for
professionals)
• Group 3 combined the interventions for patients and
professionals (combined intervention)
In the usual care or control group, neither patients or families
nor physicians or nurses received any additional educational or
supporting activities beyond the usual activities provided by
the PHCP. The full study protocol has been reported elsewhere
[13].
Study Participants
The INDICA study included patients with T2DM aged between
18 and 65 years, diagnosed at least 1 year before study
enrollment, without diabetes-related complications, and who
regularly used a mobile phone (Textbox 1 provides more
details).
JMIR Mhealth Uhealth 2020 | vol. 8 | iss. 11 | e18922 | p. 2https://mhealth.jmir.org/2020/11/e18922
(page number not for citation purposes)
Ramallo-Fariña et alJMIR MHEALTH AND UHEALTH
XSL•FO
RenderX
Textbox 1. Patients’ inclusion and exclusion criteria.
Patient inclusion criteria:
• Patients with type 2 diabetes mellitus diagnosed at least 1 year before study enrollment
• Aged between 18 and 65 years
• Formal consent to participate in the study
• Regular usage of mobile phone
Patient exclusion criteria:
• Chronic kidney disease ≥ stage 3b, as defined by the National Kidney Foundation’s Kidney Disease Outcomes and Quality Improvement Initiative,
urinary albumin to creatinine ratio ≥ 300 mg/g, or urinary protein excretion ≥ 300 mg/24 hours
• Acute coronary syndrome (documented angina or myocardial infarction) or stroke in the last 6 months or class III or IV heart failure, according
to the New York Heart Association
• Proliferative diabetic retinopathy or clinically significant diabetic macular edema requiring previous treatment with retinal photocoagulation,
vitrectomy, or intravitreal injections of antivascular endothelial growth factor or triamcinolone acetonide 6 months before study inclusion
• Uncorrected severe hearing or visual impairment or corrected visual acuity ≤ 20/40 by any cause
• Diabetic foot with ulcers ≥ 2 according to the Wagner scale
• Liver cirrhosis
• Cancer, unless disease free 5 years after diagnosis
• Other terminal illnesses
• Intellectual retardation, dementia, and psychotic diseases
• Active substance abuse, alcohol, or drugs (must be sober for 1 year)
• Pregnancy
• Insufficient (Spanish) language skills
• Physical disability limiting participation in group education activities
• Concurrent participation in another clinical trial or any other investigational study
The family care unit (FCU) in each PHCP, comprising a family
physician and a nurse responsible for the same set of patients,
was the unit of recruitment. FCUs either planning or awaiting
placement changes among PHCP in the first 6 months after
project initiation were excluded.
All PHCPs included had to have at least eight FCUs and the
availability of appropriate places to provide educational group
sessions.
Setting and Recruitment
PHCPs were recruited in 4 Canary Islands (Tenerife, Gran
Canaria, Lanzarote, and La Palma). FCUs were randomly
selected from all consenting FCUs at each PHCP. The electronic
clinical records (ECRs) of all potentially eligible patients in all
selected FCUs were screened to verify inclusion and exclusion
criteria. Finally, eligible patients were randomly selected per
FCU.
Random Assignment
Randomization was performed at different levels. First, 3
different strata were created according to the geographical areas
in the more populated islands (Tenerife and Gran Canaria).
Second, 4 PHCP (clusters) were randomly allocated to every
geographical stratum, and block permutation was used to assign
PHCPs to the study arms (in total 12 PHCPs for each island),
with PHCP as the sampling unit. La Palma and Lanzarote (less
populated islands) were geographically divided into 4 zones
with only 1 eligible PHCP available in each zone, which was
randomly assigned to one of the study arms. On every island,
all arms were equally distributed. A total of 6 FCUs were
randomly selected from all those consenting to participate in
each PHCP. Furthermore, 15 patients were randomly selected
from all patients fulfilling the inclusion criteria and consenting
to participate in each FCU. Exceptionally, more than 6 FCUs
or more than 15 patients per FCU were selected to recruit 90
patients at every PHCP.
FCU and patient randomizations were performed by simple
generation from a list of random numbers.
Cluster allocation avoids contamination bias among participants,
also facilitating logistics in group interventions.
Interventions
Patient Interventions
Patients recruited to the intervention for patients and combined
intervention groups received a complex intervention of
knowledge transfer and behavior modification, informed by
conceptual frameworks of behavioral change [14]. Key
determinants of behavior change suggested by Michie et al [14]
were considered for intervention design and implementation,
including social and professional role and identity, knowledge,
skills, beliefs about capabilities, beliefs about consequences,
JMIR Mhealth Uhealth 2020 | vol. 8 | iss. 11 | e18922 | p. 3https://mhealth.jmir.org/2020/11/e18922
(page number not for citation purposes)
Ramallo-Fariña et alJMIR MHEALTH AND UHEALTH
XSL•FO
RenderX
motivation and goals, memory, attention and decision processes,
environmental context and resources, social influences, emotion,
and action planning. Linked to these construct domains,
interventions included all techniques judged as effective by the
same authors [14], combining (1) a conventional group
educational program with a set of 8 quarterly 3-hour group
sessions; (2) monitoring of physical activity, diet, drug
adherence, mood, blood pressure, and blood glucose readings
by daily usage of paper workbooks, complemented by weekly
access to a website to download paper workbook data
(Multimedia Appendix 1); and (3) continuous personalized
feedback by semiautomated mobile phone messages based on
the results from the website.
Interventions for Primary Care Professionals
Primary care professionals recruited to the intervention for
professionals and combined intervention groups received a
complex intervention of knowledge transfer and decision
support, partially addressing the determinants of behavior
change suggested by Michie et al [14] for its design and
implementation, including only techniques to improve skills,
environmental changes, prompts and cues by means of electronic
clinical guidelines linked to the ECR, processes for encouraging
and supporting doctors and nurses, persuasive communication,
and periodic feedback on outcomes compared with other
colleagues. The interventions combined (1) an educational and
interactive group program of 2 sessions to update clinical
management and promote patient-centered care; (2) an
automated decision aid tool based on a CPG for T2DM,
embedded into the ECR (Multimedia Appendix 2); and (3)
monthly computerized graphic feedback, displaying a set of
processes and outcome indicators for all patients with T2DM
of the corresponding FCU.
To maintain the fidelity of interventions, a manual was
developed for each intervention. Furthermore, all group sessions
were recorded and reviewed.
Both interventions were applied during the 2 years of follow-up
(Figure 1).
Figure 1. Arm’s intervention timeline and follow-up points.
Duration of Fieldwork
Fieldwork took place between February 2013 and October 2016.
The first year was devoted to the recruitment of patients and
health care providers and the following 2 years to the
intervention and follow-up. As interventions were maintained
over time, the intervention and follow-up periods overlapped.
Outcomes
Primary End Point
The primary outcome was the mean change in HbA1c levels
from baseline to 24 months of follow-up. HbA1c was also
measured at 3, 6, 12, and 18 months. We considered a change
in HbA1c of 0.4% as clinically significant [15], just between the
thresholds of 0.3% reported by National Institute for Health and
Care Excellence [16] and 0.5% by the United Kingdom
Prospective Diabetes Study [17].
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BMI, weight, waist circumference, waist-to-hip ratio, systolic
blood pressure (SBP), and diastolic blood pressure (DBP) were
also assessed at baseline and after 3, 6, 12, 18, and 24 months.
Total, high-density lipoprotein (HDL), and low-density
lipoprotein (LDL) cholesterol, triglycerides, and fasting serum
glucose were assessed at baseline and after 6, 12, and 24 months.
Serum creatinine and glomerular filtration rate were measured
at baseline and at 12 and 24 months. Demographic data and
disease history were recorded at baseline. Health status and
current medications were also recorded at each follow-up.
Statistical Analysis
The main analysis for primary and secondary end points were
multilevel mixed models including the baseline value of the
dependent variable and the time elapsed since diagnosis (in
years) as covariates. The null hypothesis for each end point is
that the mean change with regard to the usual care arm and the
interactions between each arm and time (follow-up) are the
same across arms and equal to zero. The alternative hypothesis
is that the changes are not equal to zero. First-level variables
are those corresponding to each measurement along follow-up
(repeated time measurements), the second level includes
patients’ variables, and third-level variables correspond to
PHCPs. The mean change was estimated at the observation
level. The effect that identifies the intervention arm was
considered fixed for the PHCPs, whereas the intercept was
considered random. The model also included an interaction term
between arm and month, allowing for differences in the
intervention effect between follow-up assessments [18]. In
addition, to summarize the global treatment effect throughout
the whole study period, differences were also calculated for the
area under the curve (AUC) of HbA1c and other continuous
variables between the different interventions and the usual care
group. Furthermore, we examined whether the most intensive
intervention, the combined intervention group (intervention for
patients plus intervention for professionals), was better than the
intervention for patients and intervention for professionals
groups on their own.
The adjusted estimated mean was calculated for each moment
of follow-up compared with baseline, and its significance was
calculated using the model already set out.
A post hoc analysis was performed for the primary end point,
HbA1c, considering the patient subsample with baseline HbA1c
higher than 7%.
To accommodate missing values in the effect analyses, the
multiple imputation procedure in Stata 15.0 software (Stata
Corporation) was used [19], with results based on 100 imputed
data sets. This procedure saves cases for the analysis and can
be considered an intention-to-treat analysis. Analysis under
multiple imputation is valid for randomly missed data [20]. The
model of imputation used and further details on data analysis
are outlined in Multimedia Appendix 3. A threshold of .05 was
used to define the statistical significance of those tests.
Sample Size Calculation
We estimated the sample size requirement of 448 patients per
study arm to detect an absolute difference in HbA1c of 0.4%,
assuming a common standard deviation of 1.4% [15], a
two-tailed power of 90%, an alpha of .05, and an adjustment
for clustering of patients within the FCU by the design effect
[21], 15 patients per FCU, and an intraclass correlation
coefficient (ICC) of 0.01 (interquartile range 0-0.032) [22]. The
intraclass correlation within PHCPs was insignificant as they
are formed of several FCUs sharing administrative management
and some additional services whose potential effects were
already controlled by means of the stratification. Despite this
consideration, the sample size was increased by an additional
30% to accommodate for expected losses to follow-up and to
warrant the presence of each study arm in all islands. Hence,
we aimed to obtain a total sample size of 2330.
Ethics Approval and Consent to Participate
All participants provided written informed consent. The
scientific and ethics committees of both the University Hospital
of Canarias and the University Hospital Nuestra Señora de la
Candelaria approved the study protocol. The study was
performed in accordance with Good Clinical Practice standards,
applicable local regulatory requirements, and the
recommendations of the Declaration of Helsinki.
Results
Study Participants
A total of 32 PHCPs with a mean of 6.6 (SD 0.9) FCUs were
included (211 professionals), with 8 PHCPs allocated to each
of the 4 study arms. Every PHCP enrolled a mean of 72.9 (SD
14.1) patients (12 patients per FCU), totaling 2334 patients.
Figure 2 shows the flowchart for the patients taking part.
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Figure 2. CONSORT (Consolidated Standards of Reporting Trials) flow diagram.
Table 1 shows the patients’ baseline characteristics according
to the intervention assignment. The mean age of the whole
population was 55.7 (SD 7.1) years, with 51.9% (1212/2334)
being women. The mean basal HbA1c value was 7.3% (SD 1.5).
Overall, 53.4% (1246/2334) of patients had HbA1c levels within
the accepted therapeutic goal (≤7%). There were no statistically
significant differences among the groups in terms of their
baseline characteristics.
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Table 1. Baseline characteristics of patients.
UCd (n=586)CBIc (n=557)PFIb (n=654)PTIa (n=537)Characteristics
55.2 (7.3)55.5 (7.1)56.2 (7.0)55.9 (7.0)Age (years), mean (SD)
286 (48.8)264 (47.4)288 (44.0)284 (52.9)Gender (male), n (%)
Smoking status, n (%)
145 (24.7)109 (19.6)156 (23.9)114 (21.2)Current smokers
240 (41.0)225 (40.4)280 (42.8)223 (41.5)Former smokers
201 (34.3)223 (40.0)218 (33.3)200 (37.2)Nonsmoker
Education, n (%)
379 (64.7)347 (62.3)409 (62.5)323 (60.2)Primary or less
157 (26.8)147 (26.4)176 (26.9)159 (29.6)High school
50 (8.5)63 (11.3)69 (10.6)55 (10.2)Bachelor’s degree or higher
Income per person in the household per month, n (%)
146 (24.9)121 (21.7)139 (21.2)118 (21.9)<€250 (US $325)
264 (45.1)272 (48.8)323 (49.4)229 (42.7)€250-€499 (US $325-$649)
96 (16.3)122 (14.2)99 (15.2)86 (16.0)€500-€649 (US $650-$844)
80 (13.7)64 (15.3)93 (14.2)104 (19.4)>€750 (US $975)
BMI categories, n (%)
44 (7.5)45 (8.1)58 (8.9)52 (9.7)Normal or underweight (<25)
197 (33.6)181 (32.5)183 (28.0)164 (30.5)Preobese (<30)
195 (33.3)175 (31.4)227 (34.7)200 (37.2)Obese class 1 (<35)
99 (16.9)103 (18.5)122 (18.7)77 (14.3)Obese class 2 (<40)
51 (8.7)53 (9.5)64 (9.8)44 (8.2)Obese class 3 or 4 (≥40)
32.1 (6.0)32.1 (5.8)32.4 (6.0)31.6 (5.7)BMI (kg/m2), mean (SD)
8.6 (6.8)8.9 (6.3)8.2 (6.1)8.4 (6.8)Duration of diabetes (years), mean (SD)
Diabetes treatment, n (%)
53 (9.0)26 (4.7)60 (9.2)40 (7.5)Only lifestyle
395 (67.4)413 (74.1)445 (68.0)394 (73.4)Oral
25 (4.3)17 (3.1)17 (2.6)12 (2.2)Injectable (insulin or GLP-1e)
98 (16.7)98 (17.6)114 (17.4)85 (15.8)Oral+injectable
15 (2.6)3 (0.5)18 (2.8)6 (1.1)Do not know/not answered
HbA1c
f categories, n (%)
304 (51.9)241 (43.3)351 (53.7)258 (48.0)<7%
141 (24.1)165 (29.6)165 (25.2)146 (27.2)7.0%-8.0%
67 (11.4)82 (14.7)75 (11.5)66 (12.3)8.1%-9.0%
74 (12.6)69 (12.4)63 (9.6)67 (12.5)>9.0%
7.3 (1.5)7.4 (1.5)7.2 (1.4)7.3 (1.5)HbA1c (%), mean (SD)
Comorbidities, n (%)
382 (67.1)363 (65.2)434 (66.4)323 (60.3)Hypertension
367 (64.0)349 (62.7)448 (68.0)353 (65.7)Hypercholesterolemia
27 (3.9)26 (4.67)39 (6.0)32 (6.0)Coronary artery disease
14 (2.1)13 (2.3)5 (0.8)12 (2.2)Ictus
57 (11.8)57 (9.7)76 (11.6)68 (12.7)Thyroid gland disorders
JMIR Mhealth Uhealth 2020 | vol. 8 | iss. 11 | e18922 | p. 7https://mhealth.jmir.org/2020/11/e18922
(page number not for citation purposes)
Ramallo-Fariña et alJMIR MHEALTH AND UHEALTH
XSL•FO
RenderX
aPTI: intervention only for patients and family members.
bPFI: intervention only for health care professionals at primary care.
cCBI: combined intervention for patients and professionals.
dUC: usual care or control group.
eGLP-1: glucagon-like peptide-1.
fHbA1c: glycated hemoglobin.
The rate of attendance at educational sessions is also shown in
Figure 2. The mean number of sessions attended by patients in
the intervention for patients and combined intervention groups
was 4.3 (SD 2.7) and 4.2 (SD 2.8), respectively. Overall, 87.5%
(470/537) of the patients assigned to the intervention for patients
group attended the first of the 8 educational sessions, which
decreased to 59.2% (318/537) in the second session and to
45.8% (246/537) in the last session. In the combined intervention
group, attendance rates were 73.4% (409/557), 57.8% (322/557),
and 47.2% (263/557), respectively. All patients in the
intervention groups received SMS during the 2 years of
follow-up and had access to the web platform that contained
the video recordings of all group sessions in addition to other
educational materials. The average number of web-based
questionnaires filled in by each patient was 16.3 (SD 29.4) in
the intervention for patients group and 9.9 (SD 23.1) in the
combined intervention group. These differences were
statistically significant (P<.001) at the 2-year follow-up.
Primary End Point: HbA1c
Multimedia Appendix 4 shows the adjusted differences in the
mean HbA1c levels at each follow-up evaluation and the adjusted
differences in AUCs of HbA1c throughout the whole study for
each intervention group, in comparison with the usual care
group. Compared with usual care, intervention for patients
achieved a significant mean HbA1c reduction of  0.27 (95% CI
 0.45 to  0.10) at month 3 and  0.26 (95% CI  0.44 to  0.08) at
month 6. Differences between intervention for patients and usual
care groups were marginally significant at 12 months (P=.07).
There were no statistically significant differences in mean HbA1c
levels in the intervention for professionals and combined
intervention groups, when compared with the usual care group.
With regard to the AUC of HbA1c, the effect of intervention for
patients was marginally significant compared with usual care
(P=.06), considering all the follow-up sessions.
The mean levels of HbA1c across the study and their adjusted
differences with regard to baseline values are shown in
Multimedia Appendix 5 by the study arm. Mean HbA1c levels
of the intervention for patients group significantly improved
during the first 12 months of follow-up, showing a maximal
reduction at month 3 ( 0.35; 95% CI  0.48 to  0.22). The
differences gradually diminished over time until they
disappeared at months 18 and 24.
At month 3, a clinically relevant reduction in HbA1c (at least
0.4%) was observed in 38.6% (207/537) of participants in the
intervention for patients group and only in 20.3% (119/586) of
patients with usual care (P<.001; Multimedia Appendix 6).
Differences between both groups in the proportion of subjects
with a clinically significant decrease in HbA1c remained
statistically significant until month 12 (191/537, 35.6% vs
152/586, 26.0%; P=.006) and marginally significant until month
18. The percentage of patients with clinically relevant decrease
in HbA1c was also significantly greater in the combined
intervention group than in the usual care group at months 3, 6,
and 18.
The results of the interventions were also analyzed in the
relevant subgroup of uncontrolled patients with baseline HbA1c
>7%. As shown in Multimedia Appendix 7, for this subgroup,
the differences in the HbA1c reduction between the intervention
for patients and usual care groups were statistically significant,
favoring the intervention for patients group from months 3 to
12. The differences in HbA1c AUC between the intervention
groups and the usual care group considering the entire period
were statistically significant for the intervention for patients
and combined intervention:  0.26 (95% CI  0.48 to  0.04) and
 0.25 (95% CI  0.47 to  0.03), respectively. For the intervention
for professionals group, the differences were marginally
statistically significant (P=.09).
All interventions led to a significant reduction in HbA1c among
subjects with baseline HbA1c levels >7% across the entire study
period (Multimedia Appendix 8). The differences at 24 months
were  0.49 (95% CI  0.70 to  0.27) for intervention for patients,
 0.35 (95% CI  0.59 to  0.14) for intervention for professionals,
and  0.35 (95% CI  0.57 to  0.13) for combined intervention
(Multimedia Appendix 8). Patients with usual care showed
significant decreases in HbA1c at months 12, 18, and 24.
Finally, in the subgroup with baseline HbA1c levels >7%, the
proportion of subjects with clinically significant reductions in
HbA1c (≥0.4%) was greater in the intervention for patients group
than in the usual care group until month 12 (140/263, 53.1% vs
116/269, 43.2%; P=.049). The differences between the combined
intervention and the usual care groups were significant at month
3 (Multimedia Appendix 6).
Secondary End Points
Compared with usual care, the intervention for professionals
group had significantly lower SBP at months 3 and 18 and the
combined intervention group had significantly lower SBP at
month 24 (Multimedia Appendix 4). Compared with their
respective baseline values, mean SBP fell significantly in all
study groups, but the difference was greatest for the combined
intervention group at 24 months ( 7.5 mm Hg; 95% CI  9.8 to
 5.2; Multimedia Appendix 5). For DBP, compared with usual
care, we found significant reductions at months 3 and 24 for
intervention for professionals and at months 12 and 24 for
combined intervention (Multimedia Appendix 4). When
compared with baseline, all groups improved; the maximum
reduction was at 24 months for the combined intervention group,
with a fall of  6.7 mm Hg (95% CI  8.2 to  5.3; Multimedia
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Appendix 5). The intervention for patients did not lead to a
significant decrease in blood pressure compared with usual care
(Multimedia Appendix 4).
Comparisons in BMI between the intervention for patients and
usual care groups only attained statistically significant
differences at month 3. None of the other interventions achieved
greater BMI reductions than those observed for usual care
(Multimedia Appendix 4). Compared with the baseline values,
the mean values of BMI decreased in the intervention for
professionals group throughout the follow-up and in the usual
care group at months 3 and 24. The intervention for patients
group experienced the greatest improvement and showed a
statistically significant reduction at month 24:  0.78 kg/m2 (95%
CI  1.0 to  0.6; Multimedia Appendix 5).
Multimedia Appendices 4 and 5 contain detailed biochemical,
clinical, and anthropometric data for the whole sample.
Multimedia Appendices 7 and 8 contain these data for the
subgroup with basal HbA1c >7%.
All 4 groups showed statistically significant improvements in
total and LDL cholesterol levels at the end of follow-up. The
differences between the intervention and usual care groups were
not statistically significant. HDL cholesterol and triglyceride
levels did not reveal clinically relevant changes.
We did not detect statistically significant differences in the
comparison of intervention for patients and intervention for
professionals groups in relation to the most intensive
intervention in the combined intervention group regarding the
primary or secondary outcomes in the AUC over the follow-up
period, except for BMI, which had a difference in area of −0.29
(95% CI −0.57 to 0.01) kg/m2 in favor of the intervention for
patients group.
For most clinical results, ICC values were low in every PHCP.
Variance homogeneity was verified and thus reflected a very
small effect associated with PHCP for intervention and control
groups (similar clinical results among PHCP in every study
arm). The ICC at the patient level was broad, accounting for
considerable variations among individuals. Considering both




The INDICA study assessed the effectiveness of
multicomponent interventions to support decision making for
the main actors involved in the management of T2DM (patients,
relatives, and primary health care professionals) in many PHCPs
[13]. We hypothesized that combining conventional educational
activities with different ICT-based decision support tools would
improve HbA1c at long term (24 months) compared with usual
care.
This study revealed that the intervention for patients group
achieved a significant but temporary reduction of HbA1c,
compared with the usual care group, which lasted for 6 months,
with a gradual dilution effect from then onward. Interventions
focused on health care professionals and on both patients and
health care professionals did not translate into a significant
lowering of HbA1c, in comparison with usual care, when
evaluated in the whole study population. Even so, more than
30% of the participants belonging to the intervention for patients
and combined intervention groups attained statistically and
clinically relevant reductions in HbA1c (>0.4%). These
percentages were significantly greater than those observed in
the control group at 12 months (for the intervention for patients
group) and 18 months (for the combined intervention group).
It must be noted that, with the intention of assessing the
effectiveness of the intervention for all patients with T2DM,
the INDICA study did not limit inclusion of participants by
their HbA1c level. Therefore, the study’s power to find clinically
relevant differences for the main outcome measures could have
been insufficient, according to Jackson et al [23], as only 50.6%
(1180/2334) of all participants had baseline HbA1c
concentrations >7% (mean 7.3%, SD 1.5). Nonetheless, the
study’s sample size provided statistical power to examine the
results of patients with worse metabolic control, allowing the
comparison with other studies that limited recruitment to patients
with poor metabolic control.
As expected, the magnitude and duration of the intervention
effect was greater among patients with baseline HbA1c >7%,
mainly for the intervention for patients group, which showed a
statistically significant reduction in HbA1c, in comparison with
usual care, although the difference disappeared at 18 months.
Moreover, considering the differences in the AUC values of
HbA1c, our results provide evidence of effectiveness for both
the intervention for patients and the combined intervention
throughout the study period. These results support previous
findings reporting greater effects for interventions on patients
with higher baseline HbA1c levels [24,25]. Similarly, the
effectiveness of quality improvement strategies exclusively
focused on health care providers seems to be beneficial only
among patients with HbA1c levels >8% [26].
The Mobile Diabetes Intervention Study (MDIS) published by
Quinn et al [27] also reported a higher reduction in HbA1c over
1 year among patients with T2DM (with baseline HbA1c=9.1%)
by means of a multicomponent behavioral intervention
exclusively for patients, without detecting effects on other
relevant outcomes such as blood pressure or lipid levels.
Although MDIS provided evidence of sustained 12-month
treatment difference in HbA1c, rather than regression to the
mean, the INDICA results, for the whole sample, show a
progressive effect reduction close to the baseline HbA1c values.
Similar to MDIS, the observed reduction in HbA1c in the
INDICA subgroup with baseline HbA1c>7% remained stable
over the long term. However, evidence of long-term
effectiveness of these complex interventions is not well stated
yet because of the reduced number of studies providing results
at 12 months of follow-up and beyond [28,29].
Several systematic reviews found that interventions based on
ICTs led to significant improvements of 4% to 5% in HbA1c
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compared with usual care [12,28,30,31], with effect differences
according to the type of ICT used (internet, automated SMS,
and apps) [11,12,32]. In contrast, smaller effects than those
reported in our study for the intervention for patients and
combined intervention groups were published for individual
and group education among patients with HbA1c levels >8%
[33,34].
Beyond the reported effects on HbA1c, we also found an
improvement in blood pressure monitoring for patients included
in the 2 groups with intervening health professionals. Long-term
reductions compared with the baseline were observed in SBP
and DBP, with statistically significant differences in relation to
usual care. These combined effects on HbA1c, SBP, and DBP,
together with the improvement observed for BMI, might
contribute to enhanced cardiovascular risk [35,36], suggesting
the overall value of these comprehensive approach strategies
addressing multiple components and actors involved in T2DM
management [37]. Although some outcomes, such as the
improvement of blood pressure, might require the involvement
of health care providers, others, such as the reduction in HbA1c,
will depend largely on the patients’ intervention. Thus, our
findings provide long-term evidence on the effectiveness of
multicomponent interventions to empower patients and support
clinical decision making to improve T2DM outcomes beyond
that published by Taylor et al [29] in their systematic review
for self-management interventions for patients with chronic
conditions. The potential expected clinical benefits, associated
with the overall metabolic and cardiovascular risk improvement
provided by INDICA over 2 years, could be estimated in the
longer-term follow-up on both microvascular and macrovascular
complications and mortality [38].
Conceptual Frameworks
The assessed interventions were informed by conceptual
frameworks of behavioral change [14] and applied to a large
and heterogeneous sample of patients, caregivers, and
professionals. The INDICA intervention characteristics were
planned to increase the validity of the obtained data and the
transferability of the interventions assessed. The key
determinants of behavior change suggested by Michie et al [14]
were considered for the INDICA interventions, with a higher
degree of adherence in their design and implementation in the
case of interventions for patients than for professionals, which
could help explain the magnitude of the effect observed for
HbA1c among intervention groups. Furthermore, time
constraints, staff turnover, and self-perception of work overload
among health professionals limited the possibility of going
deeper into the following dimensions: professional role,
motivation and goals, social and professional influences,
emotions, and action planning. A detailed description of the
complex behavior change interventions applied was reported
elsewhere [13] to promote replication at other sites. Other
potential explanations for the unexpected differences between
the intervention for patients and combined intervention groups
were the higher attendance rate of patient and family members
in the educational group sessions and a significantly higher rate
of web questionnaire completion observed in the intervention
for patients group. This higher rate of questionnaire completion
was key to adjusting the individualized components of SMS
messages, providing an extended exposure to web-based
educational material. The high turnover among health care
professionals in most PHCPs included in the study, as occurs
in the real world, could also account for the lesser effect of the
intervention for professionals and the combined intervention.
To maximize effectiveness, the INDICA interventions
incorporated all the components of a technology-enabled
self-management feedback cycle, connecting patients and the
research team by using bidirectional communication, analyzing
patient-provided behavior and health data, tailoring education,
and personalizing feedback according to the eHealth Enhanced
Chronic Care Model [24,39,40].
Strengths and Limitations
This study has some limitations. First, it was difficult to obtain
a full data set because of the high number of control visits and
the duration of follow-up for many patients. Robust imputation
techniques [19] were used to minimize the impact of missing
data. Second, as previously mentioned, the high turnover among
primary care professionals included in the study could explain
the smaller than expected impact of the intervention for
professionals and the combined intervention. Third, the fact
that around 49.4% (1154/2334) of the whole patient sample had
baseline HbA1c <7% and only around 23.0% (536/2334) had
basal HbA1c levels ≥8% clearly limits the ability of interventions
to reduce HbA1c. Fortunately, the available sample size was
sufficient to find valid evidence. Fourth, similar to other reported
findings [23,26,41], our usual care group was not a proper
control group; it was subject to repetitive and intensive
follow-up activities, including 6 different follow-up visits over
the study to apply all prespecified questionnaires, in addition
to clinical and laboratory tests. This intense follow-up activity
could act as an intervention in itself, as patients might focus on
important topics on which they had to pay attention. Fifth,
INDICA interventions were not fully theory-based, making it
more difficult to understand as to what works across contexts,
populations, and behaviors. Finally, the INDICA study was not
designed to test the efficacy of every component of the complex
interventions assessed.
The strengths of the INDICA study include the pragmatic
character of the trial and its wide sample size; the random
assignment by clusters; the engagement, as research subjects,
of all actors involved in management decisions; and the
follow-up duration. Moreover, all educational group sessions
and coaching activities by SMS were recorded to monitor and
assess homogeneity, educator fidelity to interventions, and
quality delivery. Educational workshops and periodic feedback
to health care professionals were equally delivered to all
participants in the intervention for professionals and the
combined intervention.
The INDICA findings highlight the importance of conducting
trials with long follow-up periods and sufficient statistical power
to assess interventions of limited expected effect sizes but of
high potential efficiency. ICT-supported interventions enable
its extended and continuous usage by thousands of people in
need to complement and spread interventions beyond the limited
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capacity of the health care systems to deliver usual care. We
should be careful, however, to generalize the findings of
INDICA. Interventions took place through PHCPs and were
largely implemented through electronic communications. Health
and digital literacy levels of the assessed population might vary
with regard to other settings. Moreover, health care professionals
were subject to differences in workload, interest and training
in ICT used to support patients, access to CPG, and specialist
support.
The potential effects of all these factors on the different study
arms were minimized by randomization.
Future Research
Future research on the effectiveness of these complex
interventions should be complemented by the analysis of
patients’ self-reported outcomes and intervention
cost-effectiveness to fully inform clinical and health policy
decision making. The effectiveness of these interventions should
also be assessed after longer follow-up periods to allow the
measurement of relevant clinical (micro and macrovascular)
outcomes, together with the assessment of potential longer-term
reinforcement of the most cost-effective interventions in the
short term. The use of real-world data will efficiently help to
provide this valuable information. Effectiveness and
cost-effectiveness assessment according to patients’ clinical
risk and health literacy levels are also highly relevant. Additional
evidence on cost-effectiveness and budget impact analysis is
needed to support health policy decision making in cases of
limited funding to support all assessed interventions.
Theory-based research on complex interventions to promote
behavior change is also needed, rather than theory-inspired
research, if we are to achieve a sound scientific basis for the
development and reporting of such interventions. Comparative
effectiveness assessment among components of complex
interventions is also of interest, although it will require
additional funding.
Finally, qualitative research is also needed to better understand
the relationships between patient and professional
characteristics, their engagement, and the observed results.
Conclusions
We found that INDICA interventions improved long-term
metabolic control in patients with T2DM with uncontrolled
basal HbA1c values compared with the usual care group. We
also found moderate but clinically and statistically significant
effects on blood pressure reduction, contributing to reduced
overall cardiovascular risk. The increasing access to computers,
internet, and mobile phones, together with improvements in
digital literacy, regardless of social status, sex, and age, make
these complex interventions appropriate instruments to improve
patient empowerment in the continuous management of their
chronic diseases by tailoring interventions to individual needs
and extending patient support beyond the limited capacities of
conventional office-based care.
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AUC: area under the curve
CPG: clinical practice guideline
DBP: diastolic blood pressure
ECR: electronic clinical record
FCU: family care unit
HbA1c: glycated hemoglobin
HDL: high-density lipoprotein
ICC: intraclass correlation coefficient
ICT: information and communications technology
LDL: low-density lipoprotein
MDIS: Mobile Diabetes Intervention Study
PHCP: primary health care practice
RCT: randomized controlled trial
SBP: systolic blood pressure
T2DM: type 2 diabetes mellitus
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